Lumigan Versus Cosopt

Pharmaceutical Research Network

Status and phase

Completed

Phase 4

Conditions

Open-Angle Glaucoma

Treatments

Drug: dorzolamide 2%/timolol maleate 0.5% fixed combination

Drug: placebo

Drug: bimatoprost 0.03%

Study type

Interventional

Funder types

Other

Identifiers

NCT00273455

PRN 05-017

Details and patient eligibility

About

To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

adults with a diagnosis of bilateral open-angle glaucoma including: primary, pigment dispersion or exfoliation in both eyes
on no therapy the intraocular pressure should be 22-29 mm Hg inclusive at the 8:00 AM measurement
visual acuity should be 20/200 or better in each eye

Exclusion criteria

historical failure to respond to topical beta-blockers in a clinically meaningful manner
any contraindication to study medications
any anticipated change, or modification in the 6 weeks prior to Visit 1, in systemic hypertensive therapy during the trial